0001104659-24-004657.txt : 20240118 0001104659-24-004657.hdr.sgml : 20240118 20240118065643 ACCESSION NUMBER: 0001104659-24-004657 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240118 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240118 DATE AS OF CHANGE: 20240118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EAGLE PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000827871 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36306 FILM NUMBER: 24540098 BUSINESS ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 201-326-5300 MAIL ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: EAGLE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19880120 8-K 1 tm243568d1_8k.htm FORM 8-K
false 0000827871 0000827871 2024-01-18 2024-01-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 18, 2024

 

Eagle Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36306 20-8179278
(State or other jurisdiction (Commission File Number) (IRS Employer Identification No.)
of incorporation)    

 

50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ		   07677
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 326-5300

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock (par value $0.001 per share)   EGRX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On January 18, 2024, Eagle Pharmaceuticals, Inc. (the “Company”) issued a press release announcing an update on its bendamustine intellectual property portfolio. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release of the Company, dated January 18, 2024.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: January 18, 2024 EAGLE PHARMACEUTICALS, INC.
     
  By: /s/ Brian Cahill
    Brian Cahill
    Chief Financial Officer

 

 

 

 

 EX-99.1 2 tm243568d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

A picture containing clipart Description generated with very high confidence

 

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

 

WOODCLIFF LAKE, N.J. — January 18, 2024 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio.

 

On January 16, 2024, the United States Court of Appeals for the Federal Circuit affirmed the previously announced decision by the United States District Court for the District of Delaware finding that the 505(b)(2) drug applications referencing BELRAPZO® filed by Slayback Pharma Limited Liability Company (“Slayback”)1 and Apotex Inc. and Apotex Corp. (“Apotex”) did not infringe Eagle’s previously issued ‘483 patent. Slayback, Apotex, and nBaxter Healthcare Corporation (“Baxter”) launched their respective products in December of 2022.

 

Eagle is also announcing that the U.S. Patent and Trademark Office has granted U.S. Patent Nos. 11844783 (the “‘783 patent”) and 11872214 (the “‘214 patent”) covering Eagle’s innovative bendamustine liquid formulations. The patents are listed in the Orange Book for both BENDEKA® and BELRAPZO.

 

On January 17, 2024, Eagle filed lawsuits asserting that 505(b)(2) products referencing BELRAPZO marketed by Slayback, Apotex, and Baxter each infringe one or more claims of the newly issued ‘783 and ‘214 patents and requesting damages for any infringing sales of the parties’ respective accused products. Eagle intends to seek lost profits and other damages from any and all infringing sales of the defendants’ bendamustine products, as well as injunctive relief requiring the defendants to cease all sales of their infringing products until the expiration of the patents in 2031.

 

“We are pleased to maximize our intellectual property for the bendamustine franchise and will continue to take appropriate steps to enforce our rights related to the newly issued patents,” stated Michael Graves, Interim Principal Executive Officer and Interim Executive Chairman of the Board of Eagle.

 

 

1 On September 27, 2023, Azurity Pharmaceuticals acquired Slayback Pharma.

 

 

 

 

Eagle cannot predict the timing or ultimate outcome of the litigation described above or the impact of this litigation on its business. In addition, Eagle made the allegations described above based only on information currently known to it. These allegations have not been fully litigated and the information and assumptions underlying these allegations may change after the date of hereof. Moreover, notwithstanding Eagle's allegations and its views on the merits of this litigation, litigation is inherently uncertain and there can be no guarantee that the court will agree with Eagle's allegations or interpretation of applicable regulations or laws, or that Eagle will otherwise prevail in this litigation. Accordingly, the allegations described above are not intended to be statements of fact to be relied upon by Eagle's shareholders or potential investors.

 

About Eagle Pharmaceuticals, Inc.

 

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.

 

 

 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “could,” “may,” “intend,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “seek,” “continue,” “estimate,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements with respect to: the Company’s expectations relating to BENDEKA and BELRAPZO, including related litigation, including the Company's allegations with respect to infringement of its '783 and '214 patents and potential damages related thereto and the Company’s expectations with respect to enforcement of its intellectual property rights; the issuance and listing of patents for BENDEKA and BELRAPZO in the FDA’s Orange Book and related consequences therefrom; the Company’s ability to develop innovative medicines that result in meaningful improvements in patients’ lives; the ability of the Company’s products and product candidates to address underserved therapeutic areas across multiple disease states; and the Company’s ability to develop medicines with the potential to become part of the personalized medicine paradigm in cancer care. All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the completion of the review and preparation of the Company’s financial statements and internal control over financial reporting and disclosure controls and procedures and the timing thereof; the discovery of additional information; further delays in the Company’s financial reporting, including as a result of unanticipated factors; the Company’s ability to comply with its obligations under its credit agreement; the possibility that the Company will be unable to regain compliance with, or thereafter continue to comply with, the Nasdaq Listing Rules, or experience violations of additional Nasdaq Listing Rules; the possibility that the Nasdaq may delist the Company’s securities; the Company’s ability to remediate material weaknesses in its internal control over financial reporting; the Company’s ability to recruit and hire a new Chief Executive Officer; the impacts of the post- COVID-19 environment and geopolitical factors such as the conflicts between Russia and Ukraine and Gaza and Israel; delay in or failure to obtain regulatory approval of the Company’s or its partners’ product candidates and successful compliance with Federal Drug Administration, European Medicines Agency and other governmental regulations applicable to product approvals; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether the Company can successfully market and commercialize its products; the success of the Company's relationships with its partners; the outcome of litigation; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and competition from generic entrants into the market; unexpected safety or efficacy data observed during clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the risks inherent in drug development and in conducting clinical trials; risks inherent in estimates or judgments relating to the Company’s critical accounting policies, or any of the Company’s estimates or projections, which may prove to be inaccurate; unanticipated factors in addition to the foregoing that may impact the Company’s financial and business projections and guidance and may cause the Company’s actual results and outcomes to materially differ from its estimates, projections and guidance; and those risks and uncertainties identified in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on March 23, 2023, the Company’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC on May 9, 2023, and for the quarter ended June 30, 2023, filed with the SEC on August 8, 2023, and its other subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

 

Public Relations for Eagle Pharmaceuticals, Inc.:
Faith Pomeroy-Ward
T: 817-807-8044
E: faith@eagleus.com

 

 

 

 

 EX-101.SCH 3 egrx-20240118.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 egrx-20240118_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 egrx-20240118_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm243568d1_ex99-1img01.jpg GRAPHIC begin 644 tm243568d1_ex99-1img01.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 18, 2024
Entity File Number 001-36306
Entity Registrant Name Eagle Pharmaceuticals, Inc.
Entity Central Index Key 0000827871
Entity Tax Identification Number 20-8179278
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 50 Tice Boulevard
Entity Address, Address Line Two Suite 315
Entity Address, City or Town Woodcliff Lake
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07677
City Area Code 201
Local Phone Number 326-5300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock (par value $0.001 per share)
Trading Symbol EGRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm243568d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000827871 2024-01-18 2024-01-18 iso4217:USD shares iso4217:USD shares false 0000827871 8-K 2024-01-18 Eagle Pharmaceuticals, Inc. DE 001-36306 20-8179278 50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677 201 326-5300 false false false false Common Stock (par value $0.001 per share) EGRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://eagleus.com/role/Cover Cover Cover 1 false false All Reports Book All Reports egrx-20240118.xsd egrx-20240118_lab.xml egrx-20240118_pre.xml tm243568d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm243568d1_8k.htm": { "nsprefix": "egrx", "nsuri": "http://eagleus.com/20240118", "dts": { "schema": { "local": [ "egrx-20240118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "egrx-20240118_lab.xml" ] }, "presentationLink": { "local": [ "egrx-20240118_pre.xml" ] }, "inline": { "local": [ "tm243568d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://eagleus.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm243568d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm243568d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-004657-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-004657-xbrl.zip M4$L#!!0 ( !4W,EBD-T/\* , . + 1 96=R>"TR,#(T,#$Q."YX M],_T'U*^/83DH+(8&A4#J9AM(FA0(O'<5>!PVR9"29F'Y] M)=]R<9(F:9LG>?>73F=DS2BZ!F$))QU+:_A6@B8SP/"QEWK>FB?#L]Z M/0N='+]^A?2O\\:VT04!&K31.??M'@OY$?J"(VBC3\! 8,7%$;K!-#$6?D$H M"'3&HYB" NW(([71?J/I863;&^C> NXN![T*MT'I6+9=IS)9-)@_!E/N'B4 M#9]'FPD.%5:)K-3]XY$+O)^'[$C_ 2*,=#.8[%JF MOJ*\2:O!Q=AINJ[GW%[VAQG.RH'ME!+VN SN'1X>.IFWA-:0Z4C04KKE&/<( M2ZB4M9>LP1,F%6;^'#Y0%6$6O._DSCDH60I]ET-)"0U@ 2?!;XSYLZ,=&M]L MENMZWH%>+ H1,'7!170.(4ZHSN,IP92$! (+*2S&H,R,R1C[L%ZLG%/,&-?C MK'>JL!A;'!,]KY5!FTQ_VX)3^*X31^:@]VEI!.-SSKB^$BQ$@JZ5'V>T2K4 M0L)(%KE8'P_99ED24Z0^9LR.LPBN*R42@BMVG)UC 5+3LXKZVE#P"\AZKH^I MG]"=J-/\UC$+>_D>:R^XW*(!A"C;OK:9DZXEB;G_K,+V("#L6F9>[+*=/W79 M#3U')<1$6+-]68\6WU01N)3 PJ^IU&X'+<)C$(KH89ZY O+4B3+TKS-AD(DC M+>3\P\HI'FU;N:8 _8\E]XU^O=:.,[]8^GEQ^3JZ7"X48K4E7G>%YI=_G_N9 MU!J*>;)+GFU,MM>T6UXCE<$TTVV2F+Z![9(H>3LDL>(B7Q9?KH*;@QFAUJ9! M5WP0U@9=RG& *EE:=DYA]O/Q%SED,ELE,=?.0 G'2!C1IJW[V/)6I_,G9O8L M=QH"GR=,B9=M!F&64C[LUHWIAW^S1I3XO GFO\"N87>8@GKP92/0<7(U??P- M4$L#!!0 ( !4W,EC]' +[_0H ("& 5 96=R>"TR,#(T,#$Q.%]L M86(N>&ULS9U=;^.X%8;O"_0_<-V;%AC'$P$"]WPB+N?AZ/Z_J?O)$1?KR?3C MQ^/)/W^Y7D2/9(/'"5/'+2(C':5JL<4=GYZ>3O)2+6TI=RM!]3Y.)MI.5;,L M33KT-2=I3//LOVS1"E-% FCT=$PN-+]C[79K0G^_*[([+_H0'U>.=-6/(, MTW>9KTRT\-BV27 MR0F,Q-JDJJ)C!,[WD$\,9=U5[3QJU$O5:,Y%N^UJ9LSK3$ETM.8ODY@DLN[I MB?HP5A_R9LO__#'CDY&]/B,!;A#X)OK+LM6\TMA7_0515?'!:Y"\!H0R9(RKJ_WR:'&IQT-%R";3=$)8M98V6%C2+776SS93N MY7I9$)UL,63VL98@I7'>+H@K$MIO?DF8LN?)HR MU]383)JPU#5!,6(Q!J)1:%$A]D3$KUMYQDX$W?="T5*ZY@*P:J)AR(*BP^X- M!*22^V5D*3!+$S6 ]4+2ECH_W0#,MDX]#%U0G #FX%.22N^7E,4CH53=#\"L M?T"QB5W3 ALV>6DK@R(&M @,B0<;"Y?U.I<+I,&-K:F]PE/RW87/Y4X M6(1,AP,IRL.0BO-$4NTV1 ]#+:5K>@"K)C>&+"AB[-Y 5@HYRO7^(;ED\2!$ M*IT?0 R;=CQ*48!P-)WUH2'5/L&X2M((T\++E=R6=C3/HG4-"&C7A*0E# H4 MR!T(2Q&@FNO#1.F]0#+;"M%P#<\X ML-393=D>L]7]64 7!"@]YEIW;0MY Q1/,] ERY)LKYZGN]EN5D18&M>6N&(# M,J>9,,N#8 $P93)0R)#2H4+HI>?U70*6J8<8P>:8,K<$V$TV*6AJ B+!:@R@ MX:#-GRGU0L1,CDP"TSF+R>YGL@?;U=*Y90*PV83"$ 5$A=T9@$4I1KD:2;D7 M,.Y$LL%BOTBBGJFB+72+!F2TR8:I"@@.P!I 1ZE&B_G,YTRRQ+MY+$%-'I+B M>? >2D"]6UAZ;#>9 <0!H=/M$"!(!J%FE$^0YBSBXIG7'G>8\:T< / 5(U>"'N(H[E@4K+?ZX3 M1H[!]ENU;NGJL-MDRB(,B"38'2#0G+RAJ2?^H3D9"LU)T-"QYJ9_'@KEOS5]G VJ/2" M3-NJ%9B#+#Q<6M[Z8%$!:CVC0GQBDB^L;L6=X"\)B^ E,R3W @Q@VDJ-H0T/ M';O!/GZJ!;&.\SK6%(ORWB^)EOD999HF[4-,H0D/DJ:QWL&E4/M$XHZG&:;_ M3IX[3\3M8B]X6 U;(6DHPT/%9J\/F"(&R2 ?)]8EKNJ&AO55,J//7(&/R#0EKCJ:!TR9O9[+4*[S=#5>99A([<-W MK[K2I M>]PJ"J+WNYR9))1:U!0[QF+!:1(E6<+6O\B33Y%@6ZML(E= P 8U#6U%$"B MMDP.#D*DE8XAN!-$04AD1^0O :K$0N+VX<$ZVW>)74'1;UC# 2N#@*37G@F+ M#!A'M0A4A* \QB\V\S3=$O$F>"PAGA "S0,@M?0AX@29[(6J"/3)UH)$6SD_ M[H^GJV624=O)95OB;$X"S%4SDE$>!!N *9.%O SQ!W0\_>OJ;TA'.>[^&[X4 M6"6/7>PW*TZ![%-6E2L(.BQJ#BR2(%" ?9DTW'!42E&A]9&=JF'6TARCW!4 M5ENZZQN%072ZS5'KR]_H:T]#_N4N>I2F"/!"@EWF>NBWF32'_[HF" 0ZC+5. M2DHITEH?+R0,*@0=8EQGM,Q3G*GT_&*3[_]*?K"T$M Y MRVG99;-*:FD3!<%(E[-66LLBZ5Q-C)3:-1?;.,E(7)BY2AAF48)IE1[1=D6\ M/\09+0/-5^#TZ,-@:)C)%DY%F,YE6 4>4EVZOI1>/(#Q&Z'T9\9?V8+@E#,2 M%]=2;'>*NO5NGYCIL=U\: 80!X'3$(? HS,J:/RDHI .*Z^$>2'I&Z=;EF&1 MOTLN;",3H'-+#F"S28PA"H@4NS. D$J,"K6?%[2+[!'5(JOXW2&P@9#<\>O: MG::-M[:MVH"8Z30(O<-=YOPXK(V+*$^O6&9$_5Y$\D*^X R7WL#V0G+7+U5V MF3;?IK1I T*HTR#X_F05HU+%8,V4MY0Q8B:76FO>\92XH7*?.*9EL9T[II($ MA(?-5T<&&8&TU@L+BPVF]/,V31A)X8G(4+EEP6JQR4)#$A +-E\ "[D4::T7 M%BXW1*SE]/:3X*_98YF?%6P;H';+1J?E)B-6:4"L=/D#F-$AJ(C1*77]P+,[ M)!0OLBS"+;5('6,#FC68:>E" @8RUZ*%DDA=;[GA&5IR]#4E*'LDZ++\&;IZ M)OBB'E^_-!)%ZH6(8E7.8BQL"'6)G?_J"&BX]=LC+640(/7:@W^'I(I .L0Q M-;>285$_C\M-S#.R =]VZ ]Q1=!0\YJC/GT0- TT:3*5AS5/KO- I")]9C.J M)[>'EW@-D>.5L<6@L3"N*8)@!+0%+8OKOQ7@)W?>=D63Z(IR#%]E:6@<9\QK MVS.2Y1T$ 1'0=@6ER,N%*%=ZZ?_/F#V)[7,6[>\$CPA13UFEU6C5=_UM8+1; M9M[4I"9-@T(#XNPM?@$"#U6@6AT?:C.6SXMYZJ%QES/4&!@'A6]U"IWHIJE> 5NH9 ML;(*]+NJ!.6UV'Z_O+[I6GZ2F_4F^=<*IT1N^2]02P,$% @ %3# :M2)M MB$@(EX)>MH1LO?OKUU\B^W/Q6[L=#1GER7GT0<;MD9C*M]$7DM+SZ",55!$C MU=OH&^&9VR*'C%,5#62ZX-10^T71\'GT^J37)5&[#:CW&Q6)5%_O1]MZY\8L M]'FGLUPN3X1\(DNI'O5)+%-8A6-#3*:WM9VN3C<_1?$+SL3CN?LU(9I&EI?0 MYRO-+ENNW4VSR_Z)5+-.[_2TV_GG\\TXGM.4M)EPW&+:*DNY6JK*=<_.SCKY MMZ7T2+F:*%ZVT>^4W=G6;+]E ?U.3S0[UWGW;F1,3![VVF8BK\+]URYE;;>I MW>VU^]V3E4Y:)?R>_5:;?[QE7]^Y[(K!=VO]3,[5:MJ+/7[$)1387)G=[8#7M%Z,K8 MO8DF946N?6#'##-.N]E5NE';[5=9:INR'POEIA]E3[B,]QKGCK\\<%KNRSEE M3>.3F7SJ))19VKV^^^ P]',$]I\?>4-7$VT4B4U9$R<3RO/Z?UC-@:330*]* M$@^VQNI.[2L.^[0;LRL51U(E5%G695U$Q7N1.MXM-XK.@BA;43N>,[X-\E3) MU$=G0T)Z.KH+RC;1#,TKVW[B^C#D9%:-\T "Y-G% %KI!HOH!ZICQ1:.2PW8 M/260;P^5;X6WAC&7Q\X]G3'77]<5=[*E;F-X7/ 4 8+O8XX40;=($;@2(B/\ MGBZDJ@&_KP3R?H7)N\H;$N:_,Z(,57P-(7TD!L)^C0G;XQ")]X,B0C/'!P+\ M6 TD_@?JA8?'(Q+R\9QR[A(X(D![>94>B/U/3.Q^GR\ _/63.[_;4PN<_4X1 M(/XW+P7_D5ND"-Q1Q61B3^D*P/Y(#*1^ADG=XQ"5][5(H+2W4G#^@P_[P!X2 MZB'3,>%%CX9VFP[CKI!#D:/DG+4V4;'_2XD"0]\10Y&CI*$U%AL&/LB4VNM, M<%3QJZ'(41+0.I,-,[\6AIFUN^/_)4LG/V^<[K,^5D$9HR2=/E,H;,L[#<*X M!QDAOH=**&.47#-D#H7SP/I1A(]$0E>?Z#H$^D@*)8V28P;MH:"^4RPE:CUF MXM V:.DE2"[*"$8B5BJA=RY M73R0F3T>UP.9!(?TFH+0<*#DF\^PCA*4JR2QN/3FSPT3M!L*1:4<_(P(+P ! MFR\$>^]YV'MP["AY:*W-%X*]_SSL?3AVE%RTUB8F]H']>*L>Y-+S!-HKAB)' MR45K+&("S\\TM^I.R2=6S(BJHWY4 HH>,44-FT7=X8N3/&1O+Y50WHCI:K4Y M3,YW4AO"_V.+NBO):CV4.6+B&C+:] W&(N[NIH5O*M&!!,H7)5>MM-,T4A=A M18E_]]U70(&B)*!59AKF>2/=LX^Y%,'[L<43-)GJNF!U\TCUMY#?^=K M\ PVE&'UT$;#&+\K9FP/!C)-,[&Y1^-Y*N:10O&BI']!>PVC'DO.8F:8F'VV M5XB*$5[-N4H'A8R2[/F--4SX3E$7:6HON_-Y7&ZA@;J=3GTC;T@/)8Z2Z]4; MQ24_TCJCZKG\*TI!HX"2]D%--SW.T#BSP]ZZVYL\N!4SGE'F2 5EC9+R^4PU MS/:+?%#$K=0;K].)Y/[E(95"*&&4!"]@K6'(>_VHQGL@@8)%R>PJ[2"-"=>K M>$[$C/IG+U0KH8!1,KV0.;2Q=P8:>V?/''M1,CZ?*22VQ=QP>T3=3CB;$?]* MLF !\#H;3.(!JTVOW\N7_+@UW"K-^S&T'ZJQ>Z10X#A+)$/VFD:=)U>;+S^E+0 ."LH02:1KF]_YUR_DG(I1A3HJ6@27&I'[K#[RT" MC0+B,\0:NR@A^"9Y9BFI?"*H\AP#'BD4.>*S0X\]G+F7Q:3F[;FG>%E'B+BO M!!0\XD/$L%FD^6F&NCZS)_J!&++I88B_KP24/^(#Q;!9M/GS:F!//#,9?F9^ M((321IP*6VD-!?(X)9R_SS035 ?'E@,A%#+BG-=*:RB0KU.J9G90^ZCDTLPW M:SM#L#T%H- 19[8&K>+ 7_U<1UZL?PN2KU"#WTZ B-UK$NNU&W'L)E(49W*1 M$.6A'M)#N:,NK/0;;9C\K9E3M7O]E'=F9/.VT*2'^E+0**"DJU#3..?6G97\ MP5/KG@[*&S$QK3*&LV8JFW 6#[DDP>OR/1F4+V(66F$+!>][(AY5MC#Q^D[) MF%+W^$1OCS9 0@2L !H2Q/ST62AP;A?(-'6+B63\.)Y;T_HV,_F[2VW_@C<- M@N6@H<%[MM,4W[I=[ ZO=\C]02P,$% @ %3T\:U?BO-;?7R<"!?M!7MT]C \R:\;KZ@1=J6VD M)3&WC@ZOQW3 >%5?D=$,,R1W9ZVK67$@,X2XL3GBEK[F)[RG&%++ [P D-,$)*!1TM MTEL)-IN$UJ"C:\?[&)O3SCUL=WE'OR$$%9Y9ADKLR-Z\)=1=-ES=L2;1%/N- MH0&VY2R#AH>A3J1OS1: M1^>4J$H1M8ESC!I8(T4T5L;'J%[EOSP*4N7Q6_N35+THEV_@@\T!Q>.O'9U* M/;*9/L[-\#&8X09@TMGIJ+<,SQ0>"<@6D __RAK1%?COG*NX_]C#JDTV 96? M U7382TF%8!E8;6N*V1\22:/ OS)2[E\3MP ;O8,V%Q]%!]]L^ A@$>;P) > MVP-L$?M1>N16T -B\V>;P*DR6FY\6*DEDE8"[QK*!-G.1"6GL1Y(7Q&)@NF@ M#M6@2X.,4,O0L'[D/3@" BS:XW*NT&$P3J&VJ>))$>F&3G@C'1>9P!*+:0+_ M1A6%Z%POV%?HV' U@"5[(C]V6LQNE.UFC\E*7!#CH$Y(AYD">$*+(0F(E;@( MG"1#D-X./%(F8J694$1B2H:FQ1"#=2,6.%QB>SV8$2W:W#L"!8B[O.* 6TBF M8?% +1)C6XGYS0[8@=.83353)9[N^ZC"P#UTMN%: 3;HQM>XZ,\9465ISH%= M"KH2/O'IT^ESJK"6'B46XN232'=3J5^&F;0X>(8N&8G/QV8"3PUEF0KP^993 MQ0XIS:800)JU+0T#05DQ*&A9)"M$0/#09V.8MZY./<:"2BUQ4R/8=BU2\G6O M"'T"8$%3& 6#M@*^I\@K4?A,X)W>C&-F,);P@'+#,B[SEHWE2H =PYIKWIP' MBS1&09U#6B6ZH5']);0O\V41;Q3@H#W$A26&^EHYIX.>20CLWDD2QL,G^[O6 M6BYTG3/W+5%/R?(*6LJ=?:J-RH M[N_5[BJ?RXV+&JHTKZ_K[7:]V5A+WHNN^WWDW6)[ +FD8P#4:J*2V-^3A$RZ M\-M(^KU2<]YL7:,3V\0Z-ZB#B4V&+RQ M/, Z.(NR["!H%PNI]$==N5VB9G$JFW^+F(;EH /_^_X>P1"$$-M!9 CPD,7; MB7)81,!0]F_!'N47[-$-CW5K7B0<;9BN)ZWK<=4AA;ZXD6'RRDVG,3IVB@I MUZ#O0,&3"=!,]"C#%2(F5OJ"=1=;$S#<1\RS2.FU]NSWN<% +GY?G+"XRFE_ ME;U,MD7ZU&850(>5"J(7^2+W[>L/97!W-E3>Z'VB<,5*-58U0C<0@6M8)JY# M94C5CU!=EQ,?S3L=U,88K R;$5,U:SJ3_3UL(]LD,LMB%42!TXZ-P#"!IEF' MOX'6Z3.5] "3D) R5%^R3P[N NMEHJK 5YG7_(48_VYB10F^;TSS7!8Q30YD M0U6Q:4,*$/S&RSY.D$.=.$J :$@L+@3!M&&>4YBIU*#4DXB!/A@6F MCY>WVPZ8CXI7UJT8R@J)OYQ42*5;J5M*_JUFC57>6>G!(:9E#)G@A.W:*V@# MTTY4/ *+N%8='&5#3J9?S\E\B)/G5"5 0I=8T6QS[53STAQEG&_T789BAH<5 MC<1X*IL2LMOEP0;2E GQH(/'=;]J)?-56\>0SI=[Z6M&2[L/N7?^&\VK@F?,!%W:,#HDL#0CL+_8#(SE8H MCSO1E/Q7KVS4:AY4#$VC-MOC1$RHD,>WP_>"K;?:J*:9JC$!NL,K@QI&XO#C M<9P'A(P(.F]Q#K?#YL"Y; M(P+DD=U.EWQO*[]95%C);]Y3IPNMMFQBR;65% ML8AM^Q]75"=BM%W[/.GEK'OU*OWYK?6(E0ACI8P K)().C-3,GJY]--][;OP/K<5@3!6:KL4TK&4F%ECH"$?L[R]V^45DJ+F M5(%?FU;'&.G1,S+<2?9FD!5SZ6U,:(8M5KHU#$56::^'KO#3JKAD>66R4;/@ M3J!IW4!\!%9I12B&>]W/D_OG:VFXC:DLH(R5&E_>'5=XQF.J?M(*[=O$2"Z MW$2CSZ(X?6- )*H^4'-UR-N<]!YH_Z:?O]LLDU_!Z!!&B.)RV5SN%X0HX)M] M EB:9EJPR-3$*B)C(D.".639&WAJ8K\R! @68F=>[P!8A!B/#C^>Y_N5J&>U M@?_\*R^)N6-[?\\A*C$'ADZ0SL.V(Q:\J"[SN0B2(@QRJ1!>S#I8E;WQHFMLS8B(XGWL$;521'=PBR8MMJQ)3=5\$7_UJ(.<)/E::[NIU!VM/S3 M0OU,N*WA6SQX+S*'Z]4#O[A\=,'L+\GAT @0E!(2T/%=]STD5FZR*Q3,,F\C ;O;^G^>.7 MA4%,X[@HS'U_-L)1!#-WEB$Z28[T\9WL9G]M9J]WBI?.;+N M;?)\/<+U[-8%8S4MFP@(0(G+MAQB6HE+!]W#UXF+U_=O)S#5:(&IV[9+ MK!?%QI9;%4FIF:,RWK78+%&T8^%)D7CZ0'Z=\/A]=R$\VTXR6"RW.J:T:'_ M-L&B@\SYPP1>1$8LHH1XYQ^#0")7/#]" WYM+R!;PYJ/L$D7@(^*Y*.3Y=AR M-NR3&RQ')I%F:Q0\]38J_8<+]>[9AHWXZ8 M%AUQ+@CE/2,[$:4N5\(51TQ40K_*P^Y=>K,-][EP?0$/)/C@$H'O;<> //_ MQ!8:8M4EZ-]"0A!$9+(;"^ST]^%ZC_MNT7\5U[=D$'[E"@?'5WW+X=F,Z.7] M_D7N:T]FY_+;TQN7-X0D5JI=M.[^6;8W+5MF03&#,'#U^:_ZH'$OFH7JL-!_ MUVD89@V7#\)$T1$K=2#.:F!;P<^^ E]CZXDXZ.JJ\HIUWTH9?;=ULZB29%U7 M6 1/4'>"9%Z>A"%/X#D(/R"Q4#FD-H*%A?B?007'W;>,D0/!C:&9K)R(;:20 M'M6]4VE>[4G(H*6#M'/'9U/3-(!--G?,RU!"YI"=T?"R"*D;ER) !&NWOS=W M%G<1&,LLV/C#Q,>M9O*?F>49UZ>FO68A?H8J]>>5:6'&V$16IJ=Z>09!-D*P'H3 MX)'3,B]7WBM\\4YCE@=,43<(YR<:W*5<0F\1_!3O$M!"H-'D-,^CS$9@9&1L MBG)^27>[FKLO)7F9Z<;9ZZI47!2B4O&I'7J!KN78N5NJ.T1#N03;GG^AK+%$ MT[Q[^.':#NU-9@?XMDYHB_1=U3M+>EY%56K+JL%N)2=65 S8]>(_*#2L(N(5G6WRL:GO[\W=$4(L$CI":VZ_DT\ M/H10VW;!C6)D\J-%%CAT#$X&S4B@,GA]:^G4'C!26- ] MH%WJH$(A(3+'[@R@1\6U+';9R[\,QF0(XK[]/7:" >("[_A"< (8X$!>02 ] M@#!F^M*(#QR>;R1,+(6D^O3%1C/F[>\%FR# C:E9F#]=-,_:(U8E4E4>O'4) MY%00%"J!H/2H2A1?3'C0!I&6:=B$G_281EKYUZ9,1VQ=L<:CPB,6Z=EN]P= M\9:7()7B+E4] !PD!I?H84F@Q?E&D1U:^_E%!V'5 0D_A\*33?_P"@\]%TAG M0Q^G^C$ OD/G41'*D!S<9\3 M.6 M!SX%.Y3&?YRBYQ0+;W**._-_Y].LAI_69?N;@WZ1:/<^=9ZX259 MOSTLBTHI0_P4$GS/8?[E.-Y&W+-++2\ZW=];G=^A4'K'.K7"FP.*JTZ0C%U6 MT.<9J?>>%H8'\C8;R((&PWNO1)= 3M<+
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